Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab

S. D. Smith, B. J. Bolwell, L. A. Rybicki, T. Kang, R. Dean, A. Advani, S. Thakkar, R. Sobecks, M. Kalaycio, B. Pohlman, J. W. Sweetenham

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

The standard approach for relapsed diffuse large B-cell lymphoma (DLBCL) involves auto-SCT. However, studies that established this approach were conducted before the inclusion of rituximab (R) with first-line therapy became routine. Whether DLBCL patients (pts) relapsing after first-line chemoimmunotherapy including R derive a comparable benefit from auto-SCT to pts in the pre-R era is unknown. We analyzed outcomes after auto-SCT for relapsed DLBCL among pts receiving initial R and those who did not. We reviewed 257 consecutive pts with relapsed DLBCL treated at our institution with auto-SCT. In all, 226 pts were included in the analysis, of whom 161 had received no R and 65 received R as part of first-line therapy (Planned R). Median OS and relapse-free survival, measured from transplant, were similar between No R vs Planned R groups: 67 vs 44 months (P=0.3) and 25 vs 27 months (P=0.8), respectively. A further analysis was carried out between two cohorts matched by propensity analysis. Again, no differences in outcomes were observed. This suggests that auto-SCT may be equally effective in pts relapsing after first-line therapy including R, and should remain the standard of care for relapsed DLBCL.

Original languageEnglish (US)
Pages (from-to)262-266
Number of pages5
JournalBone Marrow Transplantation
Volume46
Issue number2
DOIs
StatePublished - Feb 1 2011
Externally publishedYes

Keywords

  • auto-SCT
  • diffuse large B-cell lymphoma
  • prognosis
  • rituximab

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab'. Together they form a unique fingerprint.

  • Cite this

    Smith, S. D., Bolwell, B. J., Rybicki, L. A., Kang, T., Dean, R., Advani, A., Thakkar, S., Sobecks, R., Kalaycio, M., Pohlman, B., & Sweetenham, J. W. (2011). Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab. Bone Marrow Transplantation, 46(2), 262-266. https://doi.org/10.1038/bmt.2010.95